Opinion on this:
As a breakout pharma innovation nation, we must not get bogged down in the business dogmas of pharma giants and their counterproductive short-term obsession with IPR.
www.news18.com
I got confused with license and IPR after reading the above article.
Is the owner of IPR of Sputnik V providing the various manufacturers of India with license or IPR wave off? My understanding is rather limited.
It's not that the license for Covaxin hasn't been offered to anyone outside our borders. The proposal for manufacturing of Covaxin in Bangladesh had been proposed from our side in Dec. 2020. But we are yet to hear from them.
A note on vaccine situation in Bangladesh is rather unique. A look at them will tell us how well we are positioned w.r.t vaccine situation because of our indigenous vaccine and domestic production.
Bangladesh burnt their bridge with Chinese by rejecting to sponsor ( by G.o.B) the trials of the Chinese vaccine candidate in Bangladesh. AstraZeneca rejected their ( BD) proposal to license manufacture Covishield in BD. They were cold to license manufacture Covaxin for the obvious reasons. The only means of vaccine for them was Covishield exported from India ( SII). But vaccine export ban gave them a massive blow.
Currently they are negotiating with Russia for license manufacture of Sputnik V. Whereas Russia will export Russian made Sputnik V to India until Indian production stabilizes. No such offer has been made to BD by Russia.
Chinese have made it clear to BD that no export slot of vaccine is available before Dec2021 due to prior commitments.
Thus, even with capacity constraints we are definitely in better position.
So, concluding, we had tried to do what the author has suggested, although following the license manufacture route. But the reputation of India developed vaccine, reputation (apparent) of India in the targeted country and negetive publicity of Covaxin by our own media played spoil sport.
So, once the reputation of Covaxin is further established, we might be in a position to grant license. Better wait for the efficacy of the vaccine to speak for itself.